{"id":167273,"date":"2026-11-12T12:13:07","date_gmt":"2026-11-12T20:13:07","guid":{"rendered":"https:\/\/xira.com\/p\/2026\/11\/12\/bradley-represents-castle-creek-biosciences-inc-in-proposed-combination-with-pelthos-therapeutics-inc\/"},"modified":"2026-11-12T12:13:07","modified_gmt":"2026-11-12T20:13:07","slug":"bradley-represents-castle-creek-biosciences-inc-in-proposed-combination-with-pelthos-therapeutics-inc","status":"publish","type":"post","link":"https:\/\/xira.com\/p\/2026\/11\/12\/bradley-represents-castle-creek-biosciences-inc-in-proposed-combination-with-pelthos-therapeutics-inc\/","title":{"rendered":"Bradley Represents Castle Creek Biosciences, Inc. in Proposed Combination With Pelthos Therapeutics Inc."},"content":{"rendered":"<p>BIRMINGHAM, AL\u2014Bradley is serving as legal counsel to Castle Creek Biosciences, Inc. in connection with its definitive merger agreement with Pelthos Therapeutics Inc. (NYSE American: PTHS). Through the proposed combination, Castle Creek\u2019s fibroblast-based cell and gene therapy platform would complement Pelthos\u2019 portfolio of FDA-approved products and established dermatology commercial capabilities, with a focus on serious diseases that affect the skin. The definitive merger agreement provides for Castle Creek stockholders to receive 5.2 million shares of Pelthos common stock at closing, equivalent to approximately 32.5% of Pelthos\u2019 fully diluted shares. Stockholders may also receive additional shares and milestone payments totaling up to $300 million, contingent on specified development and sales criteria and subject to the terms and conditions of the agreement.<\/p>\n<p>The Bradley team advising Castle Creek on the transaction is led by corporate partners P. Gregory Hidalgo, Patrick M. Everman, P. Cyrus Chin, and Erin Reeves McGinnis, with support from associates Ashley J. Osborne\u00a0and Hamza Mallick. The team also includes attorneys Marc Bussone, Michael S. Denniston, Stephen Hinton, Jake Neu, Eric Setterlund, Jennifer M. Trulock, Ryan P. Wheeler, and J. Michael Wilson.<\/p>\n<p>Castle Creek is a late-stage company developing redosable gene therapies. It is preparing to advance the Phase 3 program of its lead candidate, D-Fi (FCX-007), for patients with dystrophic epidermolysis bullosa (DEB), a rare genetic skin disease. The merger is positioned to expand the combined company\u2019s pipeline of therapies and support the development of new treatments.<\/p>\n<p>Following completion of the merger, the combined company will operate under the Pelthos Therapeutics Inc. name, with its shares continuing to trade on the NYSE American under PTHS. The companies\u2019 October 30, 2026 announcement anticipated closing by the end of the first quarter of 2027, subject to customary closing conditions.<\/p>\n<p>Bradley is serving as legal advisor to Castle Creek Biosciences, Inc., alongside Katten Muchin Rosenman LLP, while PHCP, LLC is serving as financial advisor. Latham &amp; Watkins LLP is serving as legal advisor to Pelthos Therapeutics Inc.<\/p>\n<p>The post <a rel=\"nofollow noopener\" href=\"https:\/\/attorneyatlawmagazine.com\/talk-of-the-town\/bradley-represents-castle-creek-biosciences-inc-in-proposed-combination-with-pelthos-therapeutics-inc\" target=\"_blank\">Bradley Represents Castle Creek Biosciences, Inc. in Proposed Combination With Pelthos Therapeutics Inc.<\/a> appeared first on <a rel=\"nofollow noopener\" href=\"https:\/\/attorneyatlawmagazine.com\/\" target=\"_blank\">Attorney at Law Magazine<\/a>.<\/p>\n<div id=\"moove_gdpr_cookie_modal\" class=\"gdpr_lightbox-hide\" role=\"complementary\" aria-label=\"GDPR Settings Screen\">\n<div class=\"moove-gdpr-modal-content moove-clearfix logo-position-left moove_gdpr_modal_theme_v1\">\n<div class=\"moove-gdpr-modal-left-content\">\n<div class=\"moove-gdpr-company-logo-holder\"><img decoding=\"async\" src=\"https:\/\/attorneyatlawmagazine.com\/wp-content\/uploads\/2020\/09\/black@0.5x.png\" alt=\"\" class=\"img-responsive\" title=\"\"><\/div>\n<\/div>\n<div class=\"moove-gdpr-modal-right-content\">\n<div class=\"main-modal-content\">\n<div class=\"moove-gdpr-tab-content\">\n<div id=\"privacy_overview\" class=\"moove-gdpr-tab-main\">Privacy Overview<\/p>\n<div class=\"moove-gdpr-tab-main-content\">\n<p>This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognizing you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful. Read our <a href=\"https:\/\/attorneyatlawmagazine.com\/privacy-policy\" rel=\"nofollow noopener\" target=\"_blank\">Privacy Policy<\/a>.<\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>BIRMINGHAM, AL\u2014Bradley is serving as legal counsel to Castle Creek Biosciences, Inc. in connection with its definitive merger agreement with Pelthos Therapeutics Inc. (NYSE American: PTHS). Through the proposed combination, Castle Creek\u2019s fibroblast-based cell and gene therapy platform would complement Pelthos\u2019 portfolio of FDA-approved products and established dermatology commercial capabilities, with a focus on serious [&hellip;]<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"_et_pb_use_builder":"","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":""},"categories":[17],"tags":[],"class_list":["post-167273","post","type-post","status-publish","format-standard","hentry","category-legal_matters"],"_links":{"self":[{"href":"https:\/\/xira.com\/p\/wp-json\/wp\/v2\/posts\/167273","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/xira.com\/p\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/xira.com\/p\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/xira.com\/p\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/xira.com\/p\/wp-json\/wp\/v2\/comments?post=167273"}],"version-history":[{"count":0,"href":"https:\/\/xira.com\/p\/wp-json\/wp\/v2\/posts\/167273\/revisions"}],"wp:attachment":[{"href":"https:\/\/xira.com\/p\/wp-json\/wp\/v2\/media?parent=167273"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/xira.com\/p\/wp-json\/wp\/v2\/categories?post=167273"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/xira.com\/p\/wp-json\/wp\/v2\/tags?post=167273"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}